Diagnostic for Predicting Parkinson's Disease

The monoclonal antibody is designed to detect DJ-1, to map the protein in regions of the brain associated with Parkinson's. The antibody was developed by Signet Laboratories, Inc. (Dedham, MA, USA), a pioneering, evidence-based medicine company committed to developing predictive diagnostics and preventive drugs for critical disease states.

"Unfortunately, Parkinson's is a very difficult disease to detect, and neurologists must rely on an evaluation of symptoms, followed by administration of anti-Parkinson's drugs to see if the patient responds,” explained Dr. Richard G. Gill, president and CEO of Signet Labs. "This is a long and difficult process, and sometimes leads to incorrect diagnoses that prevent a patient's effective treatment.”




Related Links:
Signet Labs